Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product hopping is a strategy for originators to minimise the erosion of their sales that has caught the attention of regulators and courts.
Immatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmithKline (GSK) to find novel cancer targets on solid tumours and to direct TCR-T cell therapies against them. European Biotechnology spoke with Dr Harpreet Singh, CEO of Immatics Biotechnologies.
Every year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?
While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
Spanish 3P Biopharmaceuticals has shown tremendous growth, at least 10 per cent above market growth rate in the past four years. European Biotechnology spoke with Dámaso Molero, CEO of the Spanish CDMO, about growth perspectives and future strategies.
A newly forming industry association warns the European Commission not to block patients’ access to the emerging EU market for medicinal cannabis. At the BIO-Europe in Hamburg, European Biotechnology spoke with one of the initiators, Peter Homberg.
The European biotech sector is flourishing – rising stock prices, big partnering deals, and some major M&A. Can someone please tell European fund managers that investing in biotech is simply mind over matter?!
Medical cannabis has become one of the most important economic topics in recent years! But, what makes this topic so relevant, and why is it so essential to found a European association? The legalisation of recreational and medicinal cannabis in different states has led to impressive economic progress in recent years. Through worldwide patient campaigns and global marketing strategies, the topic became a permanent information focus for social networks and politics at the end of 2018.
In 2019, a new AMR accelerator kicked off under the aegis of the Innovative Medicines Initiative as a follow-up and evolutive next step to the former New Drugs for Bad Bugs programme. European Biotechnology spoke with Rob Stavenger, its coordinator at GlaxoSmithKline, about the goals of the €295m initiative, its cooperation with SMEs, and the relevance of push and pull incentives in the field.